FDA Clears Path for First Huntington's Disease Treatment

After initially calling it a failed product, the FDA reversed course to allow accelerated approval of a groundbreaking gene therapy that could slow Huntington's disease.

The decision brings hope to 40,000 Americans living with the fatal disorder that currently has no cure.